An implantable lead includes a lead body, electrical conductors, and a lead anchor. The lead body includes an electrode segment configured to be positioned along a pericardial membrane of a heart and including a plurality of electrodes configured to at least one of sense electrical signals from the heart or deliver therapy to the heart. The electrical conductors extend through the lead body between distal and proximal ends of the lead body, and are configured to electrically couple the electrodes to a pulse generator. The lead anchor is configured to be secured to a chest wall. The electrical conductors extend through the lead anchor, and the electrode segment extends from the lead anchor to the pericardial membrane. The electrode segment includes a transition portion that is configured to extend a depth into a mediastinum and a contoured portion to extend alongside and curve about the pericardial membrane.

Devices and methods for single therapy pulse (STP) therapy for tachyarrythmia are disclosed. The STP therapy can be delivered from a far-field position to allow a “global” capture approach to pacing. Due to the global capture in STP, a series of pulses, which is indicative of conventional anti-tachycardia pacing (ATP) delivered by transvenous systems, becomes unnecessary. One to four pulses at most are needed for STP, and after delivery of the one to four pulses, therapy delivery can be interrupted to determine whether the previously delivered therapy has been successful.

An electrical stimulation method for impedance compensation is provided. The electrical stimulation method for impedance compensation is applied to an electrical stimulation device for providing high frequency electrical stimulation. In the above method, by an impedance compensation device, a high-frequency environment is provided and a first impedance value of a lead is calculated according to at least one of a measured first resistance value, a measured first capacitance value and a measured first inductance value of the lead is calculated. By the impedance compensation device, the high-frequency environment is provided and a second impedance value of the electrical stimulation device is calculated according to at least one of a measured second resistance value, a measured second capacitance value and a measured second inductance value of the electrical stimulation device. The first impedance value and the second impedance value are stored for calculating a tissue impedance.

A method for subcutaneously treating pain in a patient includes first providing a neurostimulator with an IPG body and at least a primary, a secondary, and a tertiary integral lead with electrodes disposed thereon. A primary incision is opened to expose the subcutaneous region below the dermis in a selected portion of the body. A pocket is then opened for the IPG through the primary incision and the integral leads are inserted through the primary incision and routed subcutaneously to desired nerve regions along desired paths. The IPG is disposed in the pocket through the primary incision. The primary incision is then closed and the IPG and the electrodes activated to provide localized stimulation to the desired nerve regions and at least three of the nerves associated therewith to achieve a desired pain reduction response from the patient.

In one embodiment, a neurostimulation lead for stimulating neural tissue of a patient, comprises: a lead body of insulative material; a plurality of electrodes; a plurality of terminals; a plurality of conductors, wherein the plurality of electrodes are electrically coupled to the plurality of terminals through the plurality of conductors; wherein the plurality of conductors are disposed in a helical manner in a repeating pattern of groups of conductors separated by gaps along a substantial length of the lead body, each gap being larger than an inter-conductor pitch within the groups of conductors; wherein the insulative material is a compliant material permitting elongation of the lead at low stretching forces and the insulative material of the lead body is fused through a substantial volume of the lead body and along a substantial length of the lead body.

An example medical device system includes an implantable medical lead including a first defibrillation electrode and a second defibrillation electrode, the first and second defibrillation electrodes configured to deliver antitachyarrhythmia shocks, and a pace electrode disposed between the first defibrillation electrode and the second defibrillation electrode, the pace electrode configured to deliver a pacing pulse that generates an electric field proximate to the pace electrode. The medical device system includes a shield configured to be implanted in a patient separately from the implantable medical lead and disposed anterior at least one of the electrodes, wherein the shield is configured to impede an electric field of the electrical therapy in a direction from at least one of the first defibrillation electrode, the second defibrillation electrode, or the pace electrode away from a heart of the patient.

Methods and devices are provided for activating brown adipose tissue (BAT) using electrical energy. In general, the methods and devices can facilitate activation of BAT to increase thermogenesis. The BAT can be activated by applying an electrical signal thereto that can be configured to target sympathetic nerves that can directly innervate the BAT. The electrical signal can be configured to target the sympathetic nerves using fiber diameter selectivity. In other words, the electrical signal can be configured to activate nerve fibers having a first diameter without activating nerve fibers having diameters different than the first diameter. Sympathetic nerves include postganglionic unmyelinated, small diameter fibers, while parasympathetic nerves that can directly innervate BAT include preganglionic myelinated, larger diameter fibers. The electrical signal can be configured to target and activate the postganglionic unmyelinated, small diameter fibers without activating the preganglionic myelinated, larger diameter fibers.

A medical device includes a case and a core assembly. The core assembly includes operational circuitry enclosed within a core assembly housing. The medical device also includes a battery assembly, which includes a battery enclosed within a battery housing. The case includes the core assembly housing and the battery housing. A first electrode is coupled to, and electrically isolated from, the case; and a second electrode is electrically coupled to the case. The second electrode is electrically coupled to the operational circuitry via a sensing pathway that includes a portion of the case. The battery is electrically coupled to the operational circuitry via an energy supply pathway that includes the portion of the case.

An implantable peripheral neurostimulation lead for head pain is adapted for implantation in the head for the therapeutic purpose of treating chronic head and/or face pain. The lead may include a lead body, a plurality of internal electrically conducting metal wires individually connecting to a proximal surface contact and a distal surface electrode; a distal extended metal surface electrode array; and a proximal in-line connector. The lead may be operable to provide medically acceptable therapeutic neurostimulation to multiple regions of the head, including the frontal, parietal, and occipital regions of the head simultaneously. The lead may include a supraorbital electrode array with electrodes of 3 to 5 mm in length spaced apart at 4 to 6 mm intervals. The lead may also include a temporal electrode array with electrodes of 4 to 6 mm in length spaced apart at 8 to 12 mm intervals.

The present disclosure relates to methods, devices and systems used for the treatment of medical disorders via stimulation of the superficial elements of the trigeminal nerve. More specifically, minimally invasive systems, devices and methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in the face, namely the supraorbital, supratrochlear, infraorbital, auriculotemporal, zygomaticotemporal, zygomaticoorbital, zygomaticofacial, nasal and mentalis nerves (also referred to collectively as the superficial trigeminal nerve) are disclosed herein.